SILO PHARMA, INC. Amortization of Debt Issuance Costs
SILO PHARMA, INC. (SILO) reported Amortization of Debt Issuance Costs of $39.55 thousand for the 3-month period ending 2021-06-30, per its 10-Q filed 2021-08-13.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AmortizationOfFinancingCosts · last filed 2021-08-13
- SILO PHARMA, INC. amortization of debt issuance costs for the quarter ending 2021-06-30 was $39.55K.
- SILO PHARMA, INC. amortization of debt issuance costs for the quarter ending 2021-03-31 was $39.55K.
- SILO PHARMA, INC. amortization of debt issuance costs for fiscal 2020 was $26.25K.
| Period end | Amortization of Debt Issuance Costs 3 month | Amortization of Debt Issuance Costs 6 month | Amortization of Debt Issuance Costs 12 month |
|---|---|---|---|
| 2021-06-30 | $39.55K 10-Q · filed 2021-08-13 | $79.09K 10-Q · filed 2021-08-13 | |
| 2021-03-31 | $39.55K 10-Q · filed 2021-05-17 | ||
| 2020-12-31 | $26.25K 10-K/A · filed 2021-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |